Elabela/toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension

Circulation

Volumn 135, Issue 12, 2017, Pages 1160-1173

  Yang, Peiran ^a   Read, Cai ^a   Kuc, Rhoda E ^a   Buonincontri, Guido ^b   Southwood, Mark ^c   Torella, Rubben ^a   Upton, Paul D ^d   Crosby, Alexi ^d   Sawiak, Stephen J ^b   Carpenter, T Adrian ^b   Glen, Robert C ^a,e   Morrell, Nicholas W ^d   Maguire, Janet J ^a   Davenport, Anthony P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c PAPWORTH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Apelin; Cardiopulmonary; Elabela Toddler; Pulmonary hypertension; Receptors, G protein coupled

Indexed keywords

APELIN APJ RECEPTOR; APELIN RECEPTOR; BETA ARRESTIN; ELABELA; GUANINE NUCLEOTIDE BINDING PROTEIN; MONOCROTALINE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; APELIN-13 PEPTIDE; APLN PROTEIN, HUMAN; ELA PEPTIDE, HUMAN; PEPTIDE HORMONE; SIGNAL PEPTIDE;

AGONIST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; DOWN REGULATION; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM; VASCULAR REMODELING; VASODILATATION; AGONISTS; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CATHETERIZATION; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HEART VENTRICLE; HYPERTENSION, PULMONARY; METABOLISM; MOLECULAR DYNAMICS; PATHOPHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SPRAGUE DAWLEY RAT;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CATHETERIZATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MOLECULAR DYNAMICS SIMULATION; PEPTIDE HORMONES; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 85011716026     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.023218     Document Type: Article

References (28)

1. Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci. 2015;36:560-567. doi: 10.1016/j.tips.2015.06.002.
2. Kang Y, Kim J, Anderson JP, Wu J, Gleim SR, Kundu RK, McLean DL, Kim JD, Park H, Jin SW, Hwa J, Quertermous T, Chun HJ. Apelin- APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ Res. 2013;113:22-31. doi: 10.1161/CIRCRESAHA.113.301324.
3. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. 2009;54:598-604. doi: 10.1161/HYPERTENSIONAHA. 109.134619.
4. Chng SC, Ho L, Tian J, Reversade B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell. 2013;27:672-680. doi: 10.1016/j.devcel.2013.11.002.
5. Pauli A, Norris ML, Valen E, Chew GL, Gagnon JA, Zimmerman S, Mitchell A, Ma J, Dubrulle J, Reyon D, Tsai SQ, Joung JK, Saghatelian A, Schier AF. Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science. 2014;343:1248636. doi: 10.1126/science.1248636.
6. Brame AL, Maguire JJ, Yang P, Dyson A, Torella R, Cheriyan J, Singer M, Glen RC, Wilkinson IB, Davenport AP. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension. 2015;65:834-840 doi: 10.1161/HYPERTENSIONAHA.114.05099.
7. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept. 2004;118:119-125. doi: 10.1016/j.regpep.2003.11.002.
8. Read C, Fitzpatrick CM, Yang P, Kuc RE, Maguire JJ, Glen RC, Foster RE, Davenport AP. Cardiac action of the first G protein biased small molecule apelin agonist. Biochem Pharmacol. 2016;116:63-72. doi: 10.1016/j.bcp.2016.07.018.
9. Murza A, Sainsily X, Coquerel D, Côté J, Marx P, Besserer- Offroy É, Longpré JM, Lainé J, Reversade B, Salvail D, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault É. Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions. J Med Chem. 2016;59:2962-2972. doi: 10.1021/acs. jmedchem.5b01549.
10. Macaluso NJ, Glen RC. Exploring the 'RPRL' motif of apelin-13 through molecular simulation and biological evaluation of cyclic peptide analogues. ChemMedChem. 2010;5:1247-1253. doi: 10.1002/cmdc.201000061.
11. Deng C, Chen H, Yang N, Feng Y, Hsueh AJ. Apela regulates fluid homeostasis by binding to the APJ receptor to activate Gi signaling. J Biol Chem. 2015;290:18261-18268. doi: 10.1074/jbc. M115.648238.
12. Perjés I, Kilpi T, Ulvila J, Magga J, Alakoski T, Szabó Z, Vainio L, Halmetoja E, Vuolteenaho O, Petäjä-Repo U, Szokodi I, Kerkelä R. Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart. Basic Res Cardiol. 2016;111:2. doi: 10.1007/s00395-015-0521-6.
13. Ho L, Tan SY, Wee S, Wu Y, Tan SJ, Ramakrishna NB, Chng SC, Nama S, Szczerbinska I, Sczerbinska I, Chan YS, Avery S, Tsuneyoshi N, Ng HH, Gunaratne J, Dunn NR, Reversade B. ELABELA is an endogenous growth factor that sustains hESC self-renewal via the PI3K/AKT pathway. Cell Stem Cell. 2015;17:435-447. doi: 10.1016/j.stem.2015.08.010.
14. Wang Z, Yu D, Wang M, Wang Q, Kouznetsova J, Yang R, Qian K, Wu W, Shuldiner A, Sztalryd C, Zou M, Zheng W, Gong DW. Elabela-apelin receptor signaling pathway is functional in mammalian systems. Sci Rep. 2015;5:8170. doi: 10.1038/srep08170.
15. Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J, Woods CE, Purcell NH, Catalucci D, Akasaka T, Bueno OF, Vlasuk GP, Kaliman P, Bodmer R, Smith LH, Ashley E, Mercola M, Brown JH, Ruiz-Lozano P. APJ acts as a dual receptor in cardiac hypertrophy. Nature. 2012;488:394-398. doi: 10.1038/nature11263.
16. El Messari S, Iturrioz X, Fassot C, De Mota N, Roesch D, Llorens- Cortes C. Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure. J Neurochem. 2004;90:1290-1301. doi: 10.1111/j.1471-4159.2004.02591.x.
17. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005;126:233-240. doi: 10.1016/j.regpep.2004.10.019.
18. Mayadas T, Wagner DD, Simpson PJ. von Willebrand factor biosynthesis and partitioning between constitutive and regulated pathways of secretion after thrombin stimulation. Blood. 1989;73:706-711.
19. Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus Perez V, Zamanian RT, Quertermous T, Chun HJ. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2011;31:814-820. doi: 10.1161/ATVBAHA.110.219980.
20. Szokodi I, Tavi P, Fldes G, Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysä J, Tóth M, Ruskoaho H. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91:434-440.
21. Perjés I, Skoumal R, Tenhunen O, Kónyi A, Simon M, Horváth IG, Kerkelä R, Ruskoaho H, Szokodi I. Apelin increases cardiac contractility via protein kinase Ce- and extracellular signal-regulated kinase-dependent mechanisms. PLoS One. 2014;9:e93473. doi: 10.1371/journal.pone.0093473.
22. Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, Woo YJ. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation. 2004;110(11 suppl 1):II187-II193. doi: 10.1161/01.CIR.0000138382.57325.5c.
23. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, Deng A, Eichhorn J, Mahajan R, Agrawal R, Greve J, Robbins R, Patterson AJ, Bernstein D, Quertermous T. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65:73-82. doi: 10.1016/j.cardiores.2004.08.018.
24. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD, Newby DE. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;121:1818-1827. doi: 10.1161/CIRCULATIONAHA.109.911339.
25. Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, Friis-Hansen L. Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept. 2006;133:134-138. doi: 10.1016/j.regpep.2005.09.032.
26. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA, McLean DL, Park H, Comhair SA, Greif DM, Erzurum SC, Chun HJ. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013;19:74-82 doi: 10.1038/nm.3040.
27. Alastalo TP, Li M, Perez Vde J, Pham D, Sawada H, Wang JK, Koskenvuo M, Wang L, Freeman BA, Chang HY, Rabinovitch M. Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest. 2011;121:3735-3746. doi: 10.1172/JCI43382.
28. Falcão-Pires I, Gonçalves N, Henriques-Coelho T, Moreira-Gonçalves D, Roncon-Albuquerque R Jr, Leite-Moreira AF. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009;296:H2007-H2014. doi: 10.1152/ajpheart. 00089.2009.